top of page
Traditional Library

My Research

I am one of only a few headache neurologists with an active research interest, and am ranked in the top 1.7% of authors worldwide on Migraine Disorders. 

My research interests are focused on improving access to care, novel questions on the efficacy and safety of emerging therapies and treatment options in refractory disease. 

An updated list of my peer-reviewed publications are available at Scopus, and my research activity is available through Monash University.

Research Themes

Efficacy and Safety of emerging therapies

As a local principal investigator, I am involved in running both industry, and investigator clinical trials. In addition, I have a particular research interest in better understanding the role of new migraine therapies.

Treatment options in refractory disease

Historically, there has been limited treatment options and research into refractory headache disorders. I am involved in several investigator led studies evaluating outcomes in refractory disease, as well as exploring new therapeutic options.

Improving Access and Quality of Care

Engaged in improving access and quality of care through ongoing inter-professional education, and teaching of students and doctors in training, as well as research into improving access to care.

Recent Research

  1. Gunasekera L., Ray J.C. Chilblains after galcanezumab for chronic migraine prevention: A case report (2025) Cephalalgia Reports, 8, DOI: 10.1177/25158163251322967

  2. Gonzalez-Martinez A., Ray J.C., Haghdoost F., et al. Time and headache: Insights into timing processes in primary headache disorders for diagnosis, underlying pathophysiology and treatment implications (2024) Cephalalgia, 44 (11). DOI: 10.1177/03331024241297652

  3. Ray J.C., Darby D., Butzkueven H., et al. Cognitive assessment during the phases of a spontaneous migraine: a prospective cohort study (2024) Neurological Sciences, 45 (9), pp. 4445 - 4449, DOI: 10.1007/s10072-024-07520-w

  4. Ray J.C., Dalic L., Baker J., et al. Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: Results of an Australian multicentre study. (2024) BMJ Neurology Open, 6 (1), art. no. e000547,  DOI: 10.1136/bmjno-2023-000547

  5. Cheng S., Ray J.C., Hillard T., Stark R.J. Rimegepant A new oral migraine medication. (2024). Medicine Today, 25 (1-2), pp. 35 - 37. Available here.

  6. Ray J.C., Matharu M., Hutton E. Relationship of migraine and other forms of chronic pain (2024). Handbook of Clinical Neurology, 199, pp. 517 - 524, DOI: 10.1016/B978-0-12-823357-3.00027-6

  7. Kissoon N.R., Ray J.C., Hutton E. Interventional treatments (2024). Handbook of Clinical Neurology, 199, pp. 145 - 153, DOI: 10.1016/B978-0-12-823357-3.00002-1

  8. Musubire A.K., Cheema S., Ray J.C., Hutton E.J., Matharu M. Cytokines in primary headache disorders: a systematic review and meta-analysis (2023). Journal of Headache and Pain, 24 (1), art. no. 36, DOI: 10.1186/s10194-023-01572-7

  9. Sgro M., Ray J., Foster E., Mychasiuk R. Making migraine easier to stomach: the role of the gut−brain−immune axis in headache disorders (2023) European Journal of Neurology, 30 (11), pp. 3605 - 3621, DOI: 10.1111/ene.15934

  10. Ray J., Raviskanthan S. Music medicine to improve the tolerability of onabotulinumtoxinA injections for chronic migraine: An open-label prospective cohort study (2023) BMJ Neurology Open, 5 (2), art. no. e000492, DOI: 10.1136/bmjno-2023-000492

  11. Ray J.C., Sztal-Mazer S., Baker J., et al. The short-term effects of CGRP monoclonal antibodies on bone turnover: A prospective cohort study (2023) Cephalalgia, 43 (6), Cited 4 times. DOI: 10.1177/03331024231180562

  12. Cheema S., Mehta D., Ray J.C., et al. New daily persistent headache: A systematic review and meta-analysis (2023). Cephalalgia, 43 (5), DOI: 10.1177/03331024231168089

  13. Su S., Ray J.C., Ooi C., Jain M. Pathology of MRI and second-look ultrasound detected multifocal breast cancer (2023). Acta Oncologica, 62 (12), pp. 1840 - 1845, DOI: 10.1080/0284186X.2023.2273897

  14. Ray J.C., Cheema S., Foster E., et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study (2022). Frontiers in Neurology, 13, art. no. 1036798,  DOI: 10.3389/fneur.2022.1036798

  15. Pham X., Ray J., Neto A.S., et al. Association of Neurocritical Care Services with Mortality and Functional Outcomes for Adults with Brain Injury: A Systematic Review and Meta-analysis (2022) JAMA Neurology, 79 (10), pp. 1049 - 1058, DOI: 10.1001/jamaneurol.2022.2456

  16. Ray J.C., Pham X., Foster E., et al. The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature (2022). Cephalalgia, 42 (11-12), pp. 1274 - 1287, DOI: 10.1177/03331024221095153

  17. Ray J.C., Hutton E.J. Imaging in headache disorders (2022) Australian Prescriber, 45 (3), pp. 88 - 92, DOI: 10.18773/austprescr.2022.023

  18. Ray J.C., Cheng S., Tsan K., et al. Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study (2022). Frontiers in Neurology, 13, art. no. 842082, DOI: 10.3389/fneur.2022.842082

  19. Ray J.C., Chen Z., Ramsay G., et al. Status migrainosus inpatient treatment with eptinezumab (SMITE): Study protocol for a randomised controlled trial
    (2022).     BMJ Open, 12 (3), art. no. e059647, DOI: 10.1136/bmjopen-2021-059647

  20. Ray J.C., Stark R.J., Hutton E.J. Cluster headache in adults (2022). Australian Prescriber, 45 (1), pp. 15 - 20, DOI: 10.18773/austprescr.2022.004

  21. Hilliard T., Ray J.C., Hutton E.J., Stark R.J. Migraine in 2022: An update on management
    (2022)     Medicine Today, 23 (9), pp. 57 - 64,. Available Here.

  22. Raviskanthan S., Ray J.C., Mortensen P.W., Lee A.G. Neuroimaging in Visual Snow - A Review of the Literature (2022). Frontiers in Ophthalmology, 2, art. no. 758963, DOI: 10.3389/fopht.2022.758963

  23. Ray J.C., Allen P., Bacsi A., et al. Inflammatory complications of CGRP monoclonal antibodies: a case series (2021). Journal of Headache and Pain, 22 (1), art. no. 121, DOI: 10.1186/s10194-021-01330-7

  24. Ray J.C., Hutton E.J., Matharu M. Onabotulinumtoxina in migraine: A review of the literature and factors associated with efficacy (2021). Journal of Clinical Medicine, 10 (13), art. no. 2898, DOI: 10.3390/jcm10132898

  25. Ray J.C., Hutton E.J., Cheng S. et al. New horizons in migraine therapy CGRP monoclonal antibodies (2021). Medicine Today, 22 (6), pp. 61 - 64. Available Here.

  26. Pham X., Ray J., Serpa Neto A., Udy A. Do neurocritical care units improve outcomes for brain-injured adults: A protocol for a systematic review and meta-analysis (2021) BMJ Open, 11 (3), art. no. e043981, DOI: 10.1136/bmjopen-2020-043981

  27. Ray J.C., Macindoe C., Ginevra M., Hutton E.J. The state of migraine (2021). Australian Journal of General Practice, 50 (12), pp. 915 - 921, DOI: 10.31128/AJGP-01-21-5807

  28. Ray J.C., Kapoor M., Stark R.J., et al. Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects (2021). Journal of Neurology, Neurosurgery and Psychiatry, 92 (12), pp. 1325 - 1334,  DOI: 10.1136/jnnp-2020-324674

  29. Tan L., Lin Z.C., Ray J., et al. Neurological implications of COVID-19: A review of the science and clinical guidance (2020). BMJ Neurology Open, 2 (2), art. no. e000101, 
    DOI: 10.1136/bmjno-2020-000101

  30. Schnall J.A., Khan S.F., Zolio L., Ray J.C., Jenney A.W.J. Polyneuritis cranialis from varicella zoster virus reactivation (2020). Medical Journal of Australia, 213 (8), pp. 352 - 353.e1, DOI: 10.5694/mja2.50791

  31. Sharobeam A., Ray J., Dong J., Chong V. Subacute Cerebellar Degeneration due to a Paraneoplastic Phenomenon Associated with Metastatic Merkel Cell Carcinoma: A Case Report (2017). Case Reports in Oncology, 10 (2), pp. 764 - 768, DOI: 10.1159/000479731

© 2023 Dr Jason Ray. All Rights Reserved.

bottom of page